Skip to main content
Chongqing Pharscin Pharmaceutical Co., Ltd. logo

Chongqing Pharscin Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002907 ISIN · CNE100003308 LEI · 300300M2F5XMGFAYMA24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,121 across all filing types
Latest filing 2025-07-02 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002907

About Chongqing Pharscin Pharmaceutical Co., Ltd.

https://www.pharscin.com

Chongqing Pharscin Pharmaceutical Co., Ltd. is an integrated enterprise specializing in the research, development, production, and commercialization of chemical drugs and modern traditional Chinese medicine. The company focuses on therapeutic areas such as digestive system health, cardiovascular and cerebrovascular diseases, and hepatobiliary conditions. Its portfolio includes a variety of proprietary formulations and generic medications, notably treatments for chronic liver disease and gastrointestinal disorders. Pharscin maintains advanced manufacturing facilities and a dedicated R&D infrastructure focused on enhancing drug efficacy and delivery systems. The organization emphasizes clinical value and technological innovation to provide comprehensive healthcare solutions across diverse medical sectors.

Recent filings

Filing Released Lang Actions
关于公司获得药物临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from a pharmaceutical company about receiving approval from the National Medical Products Administration for a clinical trial of a new drug. It includes details about the drug, the approval, and the impact on the company. The document is short (780 characters) and is an announcement of a regulatory approval rather than a financial report or detailed filing. It does not contain financial data, management changes, or voting results. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about a clinical trial approval, which does not fall under other specific categories.
2025-07-02 Chinese
关于控股股东及其一致行动人持股变动触及1%整数倍的公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding changes in shareholding by the controlling shareholder and related parties, detailing the reduction in shares held and compliance with prior disclosed plans. It includes specific shareholding percentages before and after the change, dates of transactions, and confirms no violation of securities laws. There is no financial report, earnings data, or management discussion. The content fits the definition of a Major Shareholding Notification, which reports changes in significant share ownership levels crossing thresholds.
2025-06-26 Chinese
关于控股股东及其一致行动人持股变动触及1%整数倍的公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding changes in shareholding by the controlling shareholder and its concerted parties, detailing the reduction in shares held and compliance with previously disclosed plans. It includes specific shareholding percentages, transaction methods, and confirms no violation of securities laws. There is no financial statement or report content, but rather a regulatory disclosure about shareholding changes. This fits the definition of a Major Shareholding Notification (MRQ). The document length is 3547 characters, which is consistent with a detailed announcement rather than a full report. Therefore, the appropriate classification is MRQ.
2025-06-10 Chinese
股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Chongqing Huashen Pharmaceutical Co., Ltd. regarding abnormal stock price fluctuations over two trading days, with explanations and confirmations about the absence of undisclosed material information affecting the stock price. It references stock codes, trading rules, and risk warnings but contains no financial statements, detailed financial data, or report attachments. The document is short (1015 characters) and serves as a regulatory disclosure about stock price behavior rather than a financial report or earnings release. This fits the category of a Regulatory Filing (RNS), which covers miscellaneous regulatory announcements that do not fit other specific categories.
2025-06-02 Chinese
关于公司痛泻宁颗粒获得新加坡注册批文的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Chongqing Huashen Pharmaceutical Co., Ltd. regarding the approval of a new drug registration certificate by the Singapore Health Sciences Authority (HSA). It details the product information, registration approval, and potential impact on the company. The document is short (1265 characters) and serves as a formal announcement of a regulatory approval event rather than a financial report or detailed operational update. It does not contain financial statements, management discussion, or detailed investor presentation content. It is not a report publication announcement since it does not mention the release of a report but rather announces a regulatory milestone. Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2025-05-29 Chinese
关于公司收到药品再注册批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Chongqing Huashen Pharmaceutical Co., Ltd. regarding the receipt of a drug re-registration approval notice from the Chongqing Drug Administration. It details the drug's registration information, indications, and the impact on the company. The document is short (1041 characters) and serves as an official announcement of regulatory approval rather than a financial report or detailed corporate filing. It does not contain financial data, management changes, or shareholder information. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-05-28 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.